Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Immunocore Holdings (IMCR) EBIAT (2023 - 2025)

Immunocore Holdings' EBIAT history spans 3 years, with the latest figure at -$30.1 million for Q4 2025.

  • For Q4 2025, EBIAT fell 26.46% year-over-year to -$30.1 million; the TTM value through Dec 2025 reached -$35.5 million, up 30.48%, while the annual FY2025 figure was -$35.5 million, 30.48% up from the prior year.
  • EBIAT for Q4 2025 was -$30.1 million at Immunocore Holdings, down from -$177000.0 in the prior quarter.
  • Across five years, EBIAT topped out at $8.7 million in Q3 2024 and bottomed at -$30.1 million in Q4 2025.
  • The 3-year median for EBIAT is -$14.3 million (2023), against an average of -$11.8 million.
  • The largest annual shift saw EBIAT soared 864.24% in 2024 before it plummeted 102.03% in 2025.
  • A 3-year view of EBIAT shows it stood at -$19.7 million in 2023, then decreased by 20.48% to -$23.8 million in 2024, then fell by 26.46% to -$30.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBIAT are -$30.1 million (Q4 2025), -$177000.0 (Q3 2025), and -$10.3 million (Q2 2025).